The great rofecoxib feeding frenzy.
Van Way
Charles W
CW
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology; D003257:Consumer Product Safety; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry / Q000331:legislation & jurisprudence; D019317:Evidence-Based Medicine; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D040541:Marketing / Q000941:ethics / Q000379:methods*; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors; D013450:Sulfones / Q000009:adverse effects*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib